Protocol Ledger

NCT03653832 · Phase III · COMPLETED

Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)

Interventional Phase III clinical trial protocol NCT03653832 sponsored by University of Edinburgh in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-11 Enrollment: 1,404 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03653832
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,404 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03653832
Protocol FieldVerified Registry Value
NCT IdentifierNCT03653832
Consolidated Lead SponsorUniversity of Edinburgh
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment1,404 participants (ACTUAL)
Registered Start Date2018-12-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03653832
Hospital Research SiteLocationSite Profile
University Hospitals Birmingham NHS Foundation TrustBirmingham, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI